Synthesis of cocrystals of sulfonyl urea class drug using suitable coformers for enhancement of aqueous solubility
Main Article Content
Abstract
The pharmaceutical cocrystals and its engineering is widely accepted phenomenon regarding to the enhancement of aqueous solubility of poorly soluble drugs. The pharmaceutical cocrystals have the great ability to improve the physicochemical properties of drug substance. Cocrystals are formed by the stoichiometric combination of drug substance and the coformer. The drug glimepiride is a third generation oral hypoglycemic sulfonylurea class. Glimepiride is a drug which is get classified as biopharmaceutical classification system (BCS) class II which indicates the glimepiride having low aqueous solubility and high permeability. Cocrystal engineering is a perfect way to increases glimepiride solubility without changing its therapeutic property. The cocrystals were synthesized by the solvent drop grinding as a green chemistry approach. The coformers used to form the cocrystals are succinic acid (SA), Theobromine (TB), caffeine (CF). The synthesized cocrystals are get characterized by vibrational spectroscopy, thermal analysis, molecular crystallography, and optical microscopy. The obtained results shows the formation of cocrystal phase between the drug glimepiride and its coformers.
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
References
- Filho S, Ferreira S, Pereira AC, et al. Synthesis of a glibenclamide cocrystal: full spectroscopic and thermal characterization. Journal of Pharmaceutical Sciences, 2018: S0022354918300789.
- Fukte SR,Wagh MP and Rawat S. Coformers Selection: An Important Tool In Cocrystal Formation. International Journal of Pharmacy and Pharmaceutical Sciences, 2014, 6(7): 9-14.
- Almarsson O and Zaworotko MJ. Crystal engineering of the composition of pharmaceutical phases. Do pharmaceutical cocrystals represent a new path to improved medicines? Chemical Communications, 2004, 17: 1889. https://doi.org/10.1039/b402150a
- Bhattia SK, Hadden DR, Montgomery DA, et al. Glibenclamide therapy in diabetes mellitus. British Medical Journal, 1970, 2(5709): 570-572. https://doi.org/10.1136/bmj.2.5709.570
- Newman A, Reutzel-Edens SM and Zografi G. Coamorphous Active Pharmaceutical Ingredient-Small Molecule Mixtures: Considerations in the Choice of Coformers for Enhancing Dissolution and Oral Bioavailability. Journal of Pharmaceutical Sciences, 2018, 107(1): 5.
- Desiraju GR. Crystal engineering: a holistic view. Angewandte Chemie (International ed. in English), 2007, 46(44): 8342-8356. https://doi.org/10.1002/anie.200700534
- Goud NR, Gangavaram S, Suresh K, et al. Novel furosemide cocrystals and selection of high solubility drug forms. Journal of Pharmaceutical Sciences, 2012, 101(2): 664-680. https://doi.org/10.1002/jps.22805
- Sathisaran I and Dalvi SV. Crystal Engineering of Curcumin with Salicylic acid and Hydroxyquinol as Coformers. Crystal Growth & Design, 2017: acs.cgd.7b00599. https://doi.org/10.1021/acs.cgd.7b00599
- Emily S and JohnW. Non-Covalent Derivatives: Cocrystals and Eutectics. Molecules, 2015, 20(8): 14833-14848. https://doi.org/10.3390/molecules200814833
- Kumar S and Nnada A. Pharmaceutical Cocrystals: An Overview. Indian journal of pharmaceutical science, 2017, 79(6): 858-871. https://doi.org/10.4172/pharmaceutical-sciences.1000302
- Filho S, Ferreira S, Pereira AC, et al. Synthesis of a glibenclamide cocrystal: full spectroscopic and thermal characterization. Journal of Pharmaceutical Sciences, 2018: S0022354918300789. https://doi.org/10.1016/j.xphs.2018.01.029
- Gao Y, Gao J, Liu Z, et al. Coformer selection based on degradation pathway of drugs: A case study of adefovir dipivoxilsaccharin and adefovir dipivoxilnicotinamide cocrystals. International Journal of Pharmaceutics (Kidlington), 2012, 438(1-2): 327-335. https://doi.org/10.1016/j.ijpharm.2012.09.027